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Abstract 
The influence of treatment with quercetin inclusion on the clinical and biochemical course 
and the cytokine profile of chronic nonviral hepatitis patients have been studied. In addition to 
the basic therapeutic treatment quercetin intake led to the decrease in the cytolytic and cholestatic 
syndromes activities which were manifested by a faster regression of clinical signs of the disease. 
During two weeks of treatment chronic hepatitis patients who received quercetin in addition to 
standard treatment, showed decrease in proinflammatory tumor necrosis factor-α by 61,9% 
(p = 0,02) and a marker of early cardiovascular injury atrial natriuretic propeptide in the blood by 
53,8% (p = 0,04). However, according to the data obtained, it is clear that for a complete 
correction of clinical manifestations of the disease, biochemical changes and the cytokine profile 
two-week appointment of complex treatment with quercetin inclusion is not enough, which 
requires longer administration of the chosen treatment course before the onset of persistent 
remission at the out-patient stage. 
Key words: chronic hepatitis, quercetin, tumor necrosis factor-α, interleukin-10, 
atrial natriuretic propeptide. 
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Introduction. Cytokines are the factors of apoptosis and necrosis of hepatocytes, playing 
an important role in the processes of inflammation and fibrogenesis of the liver tissue [8, 11]. 
Proinflammatory cytokines are important factors in the development of liver disease, while anti-
inflammatory cytokines are involved in its regeneration [7]. Sustained hyperproduction of 
proinflammatory cytokines, as a result of chronic inflammation, is one of the factors that lead to 
the development of such diseases as chronic hepatitis (CH) [14]. However, the participation of 
each cytokine in the processes of inflammation in the liver tissue requires further study. An 
important role among proinflammatory cytokines is played by tumor necrosis factor-α (TNF-α), 
which is a pleiotropic cytokine with a wide range of biological effects. In particular, it affects the 
processes of proliferation of hepatocytes, detects proinflammatory effects through the nuclear 
factor kappa B pathways and regulates liver cell apoptosis by activating caspase-8 [1, 10]. In the 
experiment on mice liver damage in animals with a decreased number of type I receptors to TNF-
α was not found to develop after a prolonged administration of ethanol [11].  
Interleukin 10 (IL-10) is an anti-inflammatory cytokine that plays a protective role against 
damaging the liver from a number of factors, in particular inhibits the development of alcohol-
mediated liver damage by activating STAT3 cellular messengers (signaling sensors and 
transcription activators) in Kupffer cells. At the same time, IL-10 inhibition stimulates the 
expression of cytokines involved in inflammation of the liver tissue [5, 6]. 
Current issue of modern hepatology is the improvement of existing treatment regimens 
for CH patients. Among the significant spectrum of substances possessing hepatoprotective 
properties, our attention has attracted by the flavonoid quercetin. Quercetin belongs to the group 
of flavonols - compounds of plant origin, the main structural element of which are two aromatic 
rings A and B, connected by a three-carbon bridge, which forms a pyranic or pyron (in the 
presence of double bonds) cycle. Flavonoids have high antioxidant activity, which is most 
pronounced in quercetin, stimulate the synthesis of proteins, regulate the exchange of 
phospholipids and have membrane-stabilizing properties [2]. Quercetin has pronounced anti-
inflammatory properties due to a decrease in the activity of 5-lipoxygenase, which reduces the 
synthesis of leukotrienes from arachidonic acid. The indicated flavonoid also reduces the activity 
of protein kinase C and calmodulin-dependent protein kinase [3, 9]. L.M. Sheremeta have 
showed that the use of quercetin contributes to the reduction of the activity of cytolytic and 
cholestatic syndromes in patients with chronic diffuse liver disease [13]. Further investigations 
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require learning the mechanisms of quercetin action in chronic nonviral hepatitis patients, in 
particular its effect on the cytokine profile of blood.  
The aim of the study was to investigate the effect of additional to the basic treatment 
administration of quercetin on the clinical course, biochemical parameters and indicators of the 
cytokine profile in chronic nonviral hepatitis patients.  
Material and methods. 55 patients with active nonviral CH were involved in the study, 
who according to the administered treatment were divided into two groups. The main group 
consisted of 25 patients with active CH who in addition to the standard treatment received pills of 
Qvertin (Quercetin) (PJSC SIC “Borshchahivskiy CPP”, Ukraine) at the dose of 40 mg (1 tablet) 
three times daily 30 minutes before taking meals within 14-16 days. 
The comparison group consisted of 30 patients with active nonviral CH who received the 
standard basic treatment comparable to those of the main group by age and gender distribution. 
The control group consisted of 45 practically healthy individuals, of the correlative age and 
gender of the patients.  
Blood samples were obtained in the morning on empty stomach from the antecubital vein 
in the first day of hospitalization before the treatment was administered. The investigation was 
performed in compliance with the Council of Europe Convention on Human Rights and 
Biomedicine and the Recommendations of the Committee on Bioethics of the Ministry of Public 
Health of Ukraine, and was approved by the Biomedical Ethics Commission of the Higher State 
Educational Establishment of Ukraine “Bukovinian State Mediсal University” (Chernivtsi, 
Ukraine). Written informed consents were obtained from all the participants.  
All of the observed patients and healthy individuals underwent comprehensive clinical, 
laboratory and instrumental diagnostic investigations. In order to exclude a viral etiology of the 
liver disease all of the patients were tested on possible hepatitis B and C infections with the help 
of polymerase chain reaction method. Biochemical studies were performed on the blood 
biochemical analyzer "Accent-200" ("Cormay SA", Poland). The range of indicators of 
biochemical blood analysis included: total bilirubin and its fractions, total protein and albumin, 
urea, creatinine, plasma enzyme activity (aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), lactate dehydrogenase (LDG), gamma-glutamyl transferase (GGT), 
alkaline phosphatase (AP)).  
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Investigation of cytokine profile was performed on immunoenzyme analyzer "Statfax 
303/Plus" ("Awareness Technology Inc.", USA). The plasma levels of TNF-α ("Bender 
MedSystems GmbH", Austria), IL-10 ("Bender MedSystems GmbH", Austria), atrial natriuretic 
propeptide (1-98) (proANP) (“Biomedica”, Austria) were investigated both in the examined 
patients and healthy individuals. 
Results and Discussion. Faster improvement of general condition, more effective 
reduction of general weakness and sensation of heaviness in the right hypochondrium, decreased 
discomfort in the heart area and shortness of breath, increased tolerance to physical activity were 
seen in patients who in addition to basic treatment received quercetin. The dynamics of the 
investigated biochemical parameters is presented in Table 1. According to these data significant 
decrease in the total bilirubin plasma concentration during treatment was observed in patients of 
both groups: by 33,5% (p= 0,008) in the main group and by 26,6% (p = 0,02) in the comparison 
group as compared to the indicators before the treatment. More effective decrease of the total 
bilirubin and its plasma fractions levels, combined with faster regression of skin and mucosal 
icterity were tyical for young patients, in comparison with mature and elderly people. 
Investigation of the enzymes reflecting cytolytic processes showed higher activity of ALT 
and AST in the blood of all patients. ALT activity in patients of the main group decreased by 
43,7% (p = 0,02), in patients of the comparison group – by 28,1% (p = 0,03) (Table 1) after the 
treatment. Significant decrease of AST activity was achieved only in patients of the main group – 
by 27,8% (p = 0,03) (Table 1). It is indicative of more effective reduction of cytolysis in these 
patients as compared to those who received only standart therapy. The obtained biochemical data 
correlated with the dynamics of clinical symptoms reflecting the general-somatic status and 
condition of the cardiovascular system. However, in spite of this, in both groups of patients, AST 
and ALT activities in the blood were still higher after the treatment in comparison with the 
mentioned parameters in practically healthy persons, indicating the need for continued therapy at 
the out-patient stage. 
There was a significant decrease in LDG activity by 16,9% (p = 0,02), as compared to 
appropriate rates before treatment in patients of the main group. Meanwhile in patients of the 
comparison group, this enzyme activity did not significantly decrease during the treatment (Table 
1). While investigating cholestasis processes higher AP activity was found in most CH patients.  
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Table1 
Biochemical blood indicators in chronic hepatitis patients in the dynamics of treatment (M±m, n, p) 
Plasma level  
Healthy 
volunteers, 
n = 45 
Comparison group, n = 30 Main group, n = 25 
Before the 
treatment  
After the treatment  
Before the 
treatment  
After the treatment  
Total bilirubin, mkmol/L  11,1 ± 0,79 
29,0 ± 4,73 
p1 < 0,001 
22,9 ± 5,01 
p1 = 0,001, p2 = 0,02 
34,3 ± 7,15 
p1 < 0,001 
25,7 ± 3,32 
p1 < 0,001, p2 = 0,008 
Direct bilirubin, mkmol/L  3,1 ± 0,31 
11,6 ± 3,58 
p1 < 0,001 
7,0 ± 1,02 
p1 < 0,001, p2 = 0,009 
15,5 ± 3,25 
p1 < 0,001 
10,3 ± 2,18 
p1 < 0,001, p2 = 0,01 
Albumin, g/L  45,0 ± 0,41 43,7 ± 1,07 
41,7 ± 1,11 
p1 = 0,001, p2 = 0,004 
43,0 ± 1,25 42,5 ± 1,57 
Total protein, g/L  69,3 ± 0,62 71,8 ± 1,26 70,8 ± 1,16 69,8 ± 1,93 70,2 ± 1,87 
Urea, mmol/L  4,2 ± 0,23 4,7 ± 0,47 4,4 ± 0,35 5,1 ± 0,39 4,3 ± 0,47 
Creatinine, mkmol/L  82,6 ± 1,80 80,0 ± 3,52 78,8 ± 3,24 83,7 ± 5,27 79,2 ± 3,87 
Aspartate aminotransferase, 
units of action/L  
22,6 ± 1,37 
57,6 ± 7,02 
p1 < 0,001 
49,6 ± 5,91 
p1 < 0,001 
62,5 ± 7,38 
p1 < 0,001 
48,9 ± 5,31 
p1 < 0,001 
p2 = 0,03 
Alanine aminotransferase, 
units of action/L  
18,5 ± 1,46 
70,6 ± 10,01 
p1 < 0,001 
55,1 ± 6,76 
p1 < 0,001, p2 = 0,03 
68,7 ± 5,43 
p1 < 0,001 
47,8 ± 5,29 
p1 < 0,001, p2 = 0,02 
Lactate dehydrogenase, 
units of action/L  
387,0 ± 
13,59 
438,1 ± 29,07 401,0 ± 25,49 
445,9 ± 31,92 
p1 = 0,01 
381,6 ± 30,82 
p2 = 0,02 
Alkaline phosphatase, units 
of action/L  
80,3 ± 3,20 
112,8 ± 9,41 
p1 = 0,01 
105,6 ± 8,34 
p1 = 0,005 
119,5 ± 14,19 
p1 = 0,02 
91,3 ± 11,57 
p2 = 0,03 
Gamma-glutamyl 
transferase, units of action/L  
21,9 ± 1,62 
107,0 ± 17,57 
p1 < 0,001 
80,4 ± 11,65 
p1 < 0,001, p2 = 0,03 
110,5 ± 11,25 
p1 < 0,001 
71,3 ± 7,95 
p1 < 0,001, p2 = 0,009 
p1 – significance of differences as compared to the indicators in the group of healthy people; p2 – significance of differences as compared to the 
indicators before the treatment.  
 
 182 
Significant decrease of AP plasma activity (by 30,9% (p = 0,03) was observed only in patients 
who received quercetin in addition to the standart treatment (Table 1). 
Similar dynamics was characteristic for GGT activity in both groups of patients, however, in 
patients of the main group, this decrease was 55,0% (p = 0,009), in the comparison group – 33,1% (p = 
0,03) (Table 2). These findings reflect the reduction of intoxication and cholestatic syndromes in the 
examined patients. These changes of biochemical parameters of blood were associated with clinical 
symptoms of the disease: improving general condition and decreasing dyspeptic disorders. More 
pronounce decrease in GGT plasma activity and a faster regression of clinical manifestations of 
intoxication and cholestatic syndromes were observed in CH patients of young age, as compared to 
older ones. 
S. Chirumbolo and G.S. Kelly repoted about quercetin anti-inflammatory properties [3, 9]. 
According to this we consider the investigation of its effect on cytokine regulation of inflammatory and 
immune processes in CH patients to be rather essential. Patients of the main group showed a significant 
decrease in TNF-α content in the blood by 61,9% (p = 0,02) ( Table 2), while patients of the 
comparison group demonstrated only the tendency to reduce this proinflammatory cytokine. The 
content of IL-10 before the initiation of treatment was elevated in the blood of the observed patients as 
compared to practically healthy people. During the treatment only the tendency towards normalization 
of its blood level was determined, which may be indicative of the need for a longer course of the 
chosen therapeutic treatment in order to achieve the normal values of the indicated anti-inflammatory 
cytokine.  
According to C. Montoliu et al. and U. Cillo et al. investigations proANP is not only a reliable 
predictor of cardiovascular risk in cardiological patients but also can serve as a marker for the risk of 
hemoynamic complications development in patients with chronic diffuse liver disease [4, 12]. Higher 
content of proANP in blood was noted in the examined patients as compared to practically healthy 
individuals, which can indicate the development of subclinical cardio-vascular insufficiency. 
Additional to the standard treatment quercetin prescription caused significant decrease of proANP level 
in patients of the main group by 53,8% (p = 0,04) (Table 2), which was accompanied by a regression of 
cardiac complaints and improvement of patient’s general condition. 
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Table 2 
Indicators of cytokine profile in the blood of chronic hepatitis patients in the dynamics of treatment (M±m, n, p) 
Plasma level  
Healthy 
volunteers, 
n = 20 
Comparison group, n = 15 Main group, n = 15 
Before the 
treatment  
After the treatment  
Before the 
treatment  
After the treatment  
Interleukin-10, pg/ml 3,9 ± 0,34 
6,3 ± 0,37 
p1 = 0,02 
5,3 ± 0,49 
6,5 ± 1,87 
p1 = 0,03 
5,1 ± 0,79 
Tumor necrosis factor-α, pg/ml 15,3 ± 0,95 
29,8 ± 4,24 
p1 = 0,004 
21,5 ± 4,77 
p1 = 0,01 
30,6 ± 5,96 
p1 = 0,01 
18,9 ± 4,88 
p2 = 0,02 
Atrial natriuretic propeptide, 
nmol/l 
1,2 ± 0,23 1,8 ± 0,26 1,5 ± 0,37 
2,0 ± 0,32 
p1 = 0,02 
1,3 ± 0,29 
p2 = 0,04 
p1 – significance of differences as compared to the indicators in the group of healthy people; p2 – significance of differences as compared to the 
indicators before the treatment. 
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Conclusions  
1. During two weeks of treatment clinical symptoms, functional liver parameters 
accompanied by a decrease in tumor necrosis factor-α and atrial natriuretic propeptide blood levels 
were more effectively corrected in chronic hepatitis patients who in addition to the standard treatment 
received quercetin.  
2. For a complete correction of clinical manifestations of the disease, biochemical changes 
and the cytokine profile two-week complex treatment with quercetin inclusion is not enough, which 
requires longer administration of the chosen treatment course before the onset of persistent remission at 
the out-patient stage.  
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